Marketing Report
Hadean Ventures closes Hadean Capital II at €144m to invest in life science startups across Europe startups

Hadean Ventures closes Hadean Capital II at €144m to invest in life science startups across Europe

European life science fund manager Hadean Ventures has announced the final close of Hadean Capital II at €144 million, substantially above target of €125 million. The fund will invest in life science startup companies across Europe with an emphasis on the Nordics and German-speaking countries. The strategy includes pharma, biotech, medtech, diagnostics and digital health.

Ingrid Teigland Akay, Managing Partner, Hadean Ventures: "We are extremely pleased to announce this very successful fundraising in a challenging environment, substantially exceeding our fundraising target. We would like to thank existing and new investors for their trust in our team and strategy, and we look forward to working with start-ups developing break-through medical solutions for tomorrow and beyond."

Magnus Skåninger CEO, Saminvest: "Saminvest is very excited to be one of the founding investors of Hadean Ventures. We firmly believe that the experienced Hadean Ventures team is well positioned to take advantage of the investment opportunities in companies that solve tomorrow's health challenges. It enables the access to venture capital and ownership experience for companies in early stages and strengthens the vibrant life science ecosystem in the Nordics." 

Hadean Capital II was launched in September 2021 and has so far invested in six companies including Alex Therapeutics, Arthex Biotech, Complement Therapeutics, Emergence Therapeutics, Ribbon Biolabs and TargED. The first exit was already successfully achieved with the acquisition of Emergence Therapeutics by Eli Lilly.

Johan Bøe Bjørkevoll, Investment Director, Investinor: "Hadean Ventures has exceeded our expectations as our first investment under Investinor's new fund in funds mandate. We are thrilled to be part of the closing of Hadean Capital II, contributing to the growth of the Norwegian and European life science ecosystem. The oversubscription of the fund demonstrates the confidence in Hadean Ventures' investment strategy and their ability to nurture promising start-ups. Together, we aim to drive groundbreaking medical advancements and make a lasting impact in life sciences. We look forward to collaborating with Hadean Ventures and fellow investors to support innovative solutions shaping the future of healthcare."